Correction: Brentuximab vedotin plus chemotherapy for the treatment of front-line systemic anaplastic large cell lymphoma: subgroup analysis of the ECHELON-2 study at 5 years’ follow-up - Poll - MDSpire

Correction: Brentuximab vedotin plus chemotherapy for the treatment of front-line systemic anaplastic large cell lymphoma: subgroup analysis of the ECHELON-2 study at 5 years’ follow-up

  • By

  • Eva Domingo-Domènech

  • Barbara Pro

  • Tim Illidge

  • Steven Horwitz

  • Lorenz Trumper

  • Swami Iyer

  • Ranjana Advani

  • Nancy L. Bartlett

  • Jacob Haaber Christensen

  • Won-Seog Kim

  • Tatyana Feldman

  • Ilseung Choi

  • Giuseppe Gritti

  • David Belada

  • Andrei Shustov

  • Arpad Illes

  • Pier Luigi Zinzani

  • Andreas Hüttmann

  • Marek Trneny

  • Steven Le Gouill

  • Deepa Jagadeesh

  • Jonathan W. Friedberg

  • Meredith Little

  • Cassie Dong

  • Michelle Fanale

  • Keenan Fenton

  • Kerry J. Savage

  • January 28, 2026

  • 0 min

Share

Original Source(s)

Correction: Brentuximab vedotin plus chemotherapy for the treatment of front-line systemic anaplastic large cell lymphoma: subgroup analysis of the ECHELON-2 study at 5 years’ follow-up

  • by Eva Domingo-Domènech, Barbara Pro, Tim Illidge, Steven Horwitz, Lorenz Trumper, Swami Iyer, Ranjana Advani, Nancy L. Bartlett, Jacob Haaber Christensen, Won-Seog Kim, Tatyana Feldman, Ilseung Choi, Giuseppe Gritti, David Belada, Andrei Shustov, Arpad Illes, Pier Luigi Zinzani, Andreas Hüttmann, Marek Trneny, Steven Le Gouill, Deepa Jagadeesh, Jonathan W. Friedberg, Meredith Little, Cassie Dong, Michelle Fanale, Keenan Fenton, Kerry J. Savage

  • January 28, 2026

Related Content

HDAC7 controls anti-viral and anti-tumor immunity by CD8+ T cells

Case Study: The Intersection of Chediak–Higashi Syndrome and Lymphoproliferative Disease Linked to Inborn Errors of Immunity

Creation and internal assessment of a nomogram tailored for lymphoma to forecast venous thromboembolism risk: analysis of a retrospective cohort comprising 790 patients